| Menopausal syndrome

Climara Pro vs Veozah

Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.

Deep comparison between: Climara Pro vs Veozah with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsVeozah has a higher rate of injection site reactions vs Climara Pro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Veozah but not Climara Pro, including UnitedHealthcare

Category

Climara Pro

Veozah

At A Glance

RouteTransdermal patch

FrequencyWeekly

ClassEstrogen/progestogen combination

RouteOral

FrequencyDaily

ClassNK3 receptor antagonist

Indications

Menopausal syndrome
Osteoporosis, Postmenopausal

Menopausal syndrome

Dosing

Menopausal syndrome, Osteoporosis, Postmenopausal 0.045 mg estradiol/0.015 mg levonorgestrel per day applied transdermally once weekly; for vasomotor symptoms, attempts to discontinue should be made at 3 to 6 month intervals.

Menopausal syndrome 45 mg tablet orally once daily with or without food.

Contraindications

Undiagnosed abnormal genital bleeding
Breast cancer or history of breast cancer
Estrogen-dependent neoplasia
Active DVT, PE, or a history of these conditions
Active arterial thromboembolic disease (e.g., stroke or MI), or a history of these conditions
Known anaphylactic reaction, angioedema, or hypersensitivity to Climara Pro
Hepatic impairment or disease
Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders

Known cirrhosis
Severe renal impairment or end-stage renal disease
Concomitant use with CYP1A2 inhibitors

Drug Interactions

1699View drug interactions

222View drug interactions

Adverse Reactions

Most common (>3%) Application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, headache, pain, flu syndrome, abdominal pain, arthralgia, edema, flatulence, hypertension, bronchitis, sinusitis, urinary tract infection

Serious Cardiovascular disorders, malignant neoplasms

Postmarketing Changes in bleeding patterns, abdominal distension, abdominal pain, nausea, alopecia, night sweats, pruritus, rash, hot flush, dizziness, headache, insomnia, application site reaction, weight increased, anaphylactic reaction

Most common (>=2%) Abdominal pain, diarrhea, insomnia, back pain, hot flush, hepatic transaminase elevation

Serious Hepatic transaminase elevation and hepatotoxicity

Postmarketing Serious drug-induced hepatotoxicity with elevated transaminases, alkaline phosphatase, and bilirubin, coupled with fatigue, nausea, pruritus, jaundice, pale feces, and dark urine

Pharmacology

Estrogen/progestogen combination; estradiol binds nuclear estrogen receptors in estrogen-responsive tissues to reduce elevated postmenopausal gonadotropin levels, while levonorgestrel inhibits gonadotropin production and counteracts the proliferative effects of estrogen on the endometrium.

Fezolinetant is an NK3 receptor antagonist that blocks neurokinin B binding on kisspeptin/neurokinin B/dynorphin neurons to modulate neuronal activity in the thermoregulatory center, with >450-fold selectivity for NK3 over NK1 or NK2 receptors.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Climara Pro